title: Skeletal manifestations of treatment of breast cancer on premenopausal women.
abstract: With increasing use of screening mammography and more effective adjuvant systemic therapies, the majority of women diagnosed with early stage breast cancer will be long-term survivors and experience personal cures. Among the common side effects of adjuvant therapies is treatment-related bone loss, primarily as a result of estrogen deprivation. Whereas this occurs in both postmenopausal and premenopausal women, this brief review will focus on pre- or perimenopausal women when initially diagnosed with breast cancer. An important distinction is between those women who retain ovarian function despite cancer or preventative treatments and the more common situation of premenopausal women who as result of cancer treatments undergo ovarian failure or early menopause. Some women with treatment-related ovarian failure will have sufficient treatment-related bone loss to be at increased risks of subsequent nontraumatic fractures and/or osteoporosis and will be candidates for antiresorptive treatments. The noncancer treatment risk factors, screening and treatments for the management of osteopenia and osteoporosis are generally the same in postmenopausal women with and without breast cancer. However, premenopausal women with relatively rapid onset of treatment-related ovarian failure and bone loss pose several challenges. Awareness of treatment-related bone loss and risks of subsequent osteoporosis is a high priority in an ever-increasing population of breast cancer survivors.
authors.affiliation: Wexner College of Medicine, The Ohio State University, Columbus, OH, USA.
authors.forename: Loomee
authors.initials: L
authors.lastname: Doo
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D000367:Age Factors; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D004164:Diphosphonates; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators